WallStSmart
VYNE

Vyne Therapeutics Inc

NASDAQ: VYNE · HEALTHCARE · BIOTECHNOLOGY

$0.67
+0.53% today

Updated 2026-05-06

Market cap
$21.39M
P/E ratio
P/S ratio
37.52x
EPS (TTM)
$-0.63
Dividend yield
52W range
$0 – $2
Volume
0.2M

Vyne Therapeutics Inc (VYNE) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20152016201720182019202020212022202320242025
Revenue$674000.00$4.58M$10.64M$1.75M$20.99M$931000.00$477000.00$424000.00$501000.00$570000.00
Revenue growth (YoY)+579.8%+132.2%-83.6%+1099.6%-95.6%-48.8%-11.1%+18.2%+13.8%
Cost of revenue$350000.00$1.39M$3.35M$4000.00$23000.00
Gross profit$674000.00$4.58M$10.64M$93000.00$19.60M$931000.00$477000.00$424000.00$501000.00$547000.00
Gross margin100.0%100.0%100.0%5.3%93.4%100.0%100.0%100.0%100.0%96.0%
R&D$2.92M$11.26M$29.01M$52.99M$53.76M$43.53M$19.54M$18.39M$16.31M$30.95M$19.24M
SG&A$1.69M$3.75M$5.17M$12.19M$22.48M$89.54M$54.48M$16.39M$13.38M$13.19M$11.08M
Operating income$-4.61M$-14.33M$-29.59M$-54.53M$-76.24M$252.55M$-38.91M$-34.30M$-29.26M$-43.64M$-29.75M
Operating margin-2126.4%-645.9%-512.5%-4356.7%1203.0%-4179.5%-7189.7%-6900.5%-8710.0%-5219.1%
EBITDA$-4.61M$-14.33M$-29.59M$-54.51M$-75.54M$-251.09M$-38.80M$-34.22M$-29.26M$-43.63M$-26.73M
EBITDA margin-2125.8%-645.7%-512.3%-4316.7%-1196.1%-4167.8%-7174.6%-6900.5%-8709.2%-4689.8%
EBIT$-4.61M$-14.33M$-29.59M$-54.53M$-76.24M$-251.44M$-38.91M$-34.30M$-29.00M$-43.64M
Interest expense$0.00$0.00$517000.00$3.09M$2.54M$4.39M$5.61M$10.81M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-4.61M$-14.07M$-29.08M$-51.45M$-70.46M$-255.57M$-73.33M$-23.21M$-28.45M$-39.83M$-26.48M
Net income growth (YoY)-205.3%-106.7%-76.9%-37.0%-262.7%+71.3%+68.3%-22.6%-40.0%+33.5%
Profit margin-2087.2%-634.6%-483.5%-4026.5%-1217.4%-7876.4%-4865.8%-6710.4%-7950.9%-4646.1%